Total Voting Rights

Ergomed plc
01 August 2023
 

 

Total Voting Rights

 

 

Guildford, UK - 1 August 2023: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

 

The Company's issued share capital as at 31 July 2023 consisted of 50,811,805 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

 

ENDS

 

Enquiries:

 

Ergomed plc                                                                           Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)      

Jonathan Curtain (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets and

Strategy)

           

Numis  (Nominated Advisor and Joint Broker)                            Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown/ Jack McLaren  

 

Peel Hunt LLP  (Joint Broker)                                                    Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

           

Consilium Strategic Communications  - for UK enquiries         Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal                                                     ergomed@consilium-comms.com

 

 

                       

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Ergomed (ERGO)
UK 100

Latest directors dealings